<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02461953</url>
  </required_header>
  <id_info>
    <org_study_id>2014-011</org_study_id>
    <nct_id>NCT02461953</nct_id>
  </id_info>
  <brief_title>Combination of Hemodialysis With Hemoperfusion：A Clinical Study</brief_title>
  <official_title>HA130 Hemoperfusion Apparatus Combined Hemodialysis to Improve Quality of Life in Patients Undergoing Maintenance Hemodialysis：A Perspective, Randomized, Controlled Multicenter Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese PLA General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, randomized, controlled multicenter clinical study. The aim of
      the study is to investigate whether the combination of maintenance hemodialysis (MHD) with
      hemoperfusion (HP) could improve the clearance rate of middle and large molecule uremic
      toxins so as to improve the quality of life of MHD patients and reduce their mortality rate.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clearance rate of uremic toxins</measure>
    <time_frame>0,3,6,12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of quality of life</measure>
    <time_frame>0,3,6,12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Renal Dialysis</condition>
  <condition>Hemoperfusion</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>low flux hemodialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low flux hemodialysis alone, 3 times a week, 4 hours per session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high flux hemodialysis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high flux hemodialysis alone, 3 times a week, 4 hours per session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low flux hemodialysis + hemoperfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low flux hemodialysis 2times a week and the HD+HP once a week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high flux hemodialysis + hemoperfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high flux hemodialysis 2times a week and the HD+HP once a week</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hemoperfusion apparatus</intervention_name>
    <arm_group_label>low flux hemodialysis + hemoperfusion</arm_group_label>
    <arm_group_label>high flux hemodialysis + hemoperfusion</arm_group_label>
    <other_name>hemoperfusion apparatus(HA-130;Jafron Biomedical Co., Ltd）</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>low flux dialyzer</intervention_name>
    <arm_group_label>low flux hemodialysis</arm_group_label>
    <arm_group_label>low flux hemodialysis + hemoperfusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>high flux dialyzer</intervention_name>
    <arm_group_label>high flux hemodialysis</arm_group_label>
    <arm_group_label>high flux hemodialysis + hemoperfusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age≥18, male or female

          2. Maintenance hemodialysis duration＞3 months

          3. Regular hemodialysis,3 times a week,4 hours per session

          4. Vascular access unlimited

          5. iPTH≥300pg/ml

          6. Sign the written informed consent

        Exclusion Criteria:

          1. Allergic to dialysis equipment

          2. PLT＜60×10^9/L

          3. Blood flow＜200ml/min

          4. Serum albumin＜30g/L

          5. Kt/V＜1.2

          6. iPTH＞800pg/ml

          7. Hemodiafiltration

          8. Coagulation disorder, severe bleeding tendency, with active bleeding

          9. Severe hypotension, severe cardiopulmonary insufficiency

         10. Under other drug trial

         11. Acute infection, severe heart, lung, liver, nervous diseases, malignant tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiangmei CHEN, Doctor</last_name>
    <phone>+86 010 66935462</phone>
    <email>xmchen301@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Delong Zhao, Doctor</last_name>
    <phone>+86 010 66935462</phone>
    <email>zhaodl1225@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangmei Chen, Doctor</last_name>
      <phone>+86 010 66935462</phone>
      <email>xmchen301@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Delong Zhao, Doctor</last_name>
      <phone>+86 010 66935462</phone>
      <email>zhaodl1225@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>May 10, 2017</last_update_submitted>
  <last_update_submitted_qc>May 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese PLA General Hospital</investigator_affiliation>
    <investigator_full_name>Xiangmei Chen</investigator_full_name>
    <investigator_title>Professor,Chief physician,Academician of Chinese Academy of Engineering,Chinese PLA General Hospital</investigator_title>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>hemoperfusion</keyword>
  <keyword>quality of life</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

